Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Operating Income (2024 - 2025)

Humacyte has reported Operating Income over the past 2 years, most recently at -$30.8 million for Q4 2025.

  • Quarterly results put Operating Income at -$30.8 million for Q4 2025, down 9.64% from a year ago — trailing twelve months through Dec 2025 was -$108.1 million (up 5.53% YoY), and the annual figure for FY2025 was -$108.1 million, up 5.51%.
  • Operating Income for Q4 2025 was -$30.8 million at Humacyte, down from -$24.4 million in the prior quarter.
  • Over the last five years, Operating Income for HUMA hit a ceiling of -$23.2 million in Q1 2025 and a floor of -$30.8 million in Q4 2025.